-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Martingale Asset Management L P Takes $805,000 Position in CureVac (NASDAQ:CVAC)
Martingale Asset Management L P Takes $805,000 Position in CureVac (NASDAQ:CVAC)
Martingale Asset Management L P acquired a new position in CureVac (NASDAQ:CVAC – Get Rating) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 41,042 shares of the company's stock, valued at approximately $805,000.
Other hedge funds have also recently bought and sold shares of the company. Capital Fund Management S.A. grew its position in CureVac by 131.9% in the 1st quarter. Capital Fund Management S.A. now owns 233,371 shares of the company's stock worth $4,576,000 after purchasing an additional 132,757 shares during the last quarter. California Public Employees Retirement System grew its holdings in CureVac by 0.6% in the 4th quarter. California Public Employees Retirement System now owns 120,622 shares of the company's stock worth $4,139,000 after buying an additional 735 shares in the last quarter. Bank of New York Mellon Corp increased its position in CureVac by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 103,549 shares of the company's stock valued at $2,030,000 after acquiring an additional 2,286 shares during the period. Eversept Partners LP acquired a new stake in CureVac in the 4th quarter valued at approximately $2,917,000. Finally, Bank of America Corp DE raised its stake in CureVac by 246.6% during the 4th quarter. Bank of America Corp DE now owns 72,885 shares of the company's stock valued at $2,501,000 after acquiring an additional 51,856 shares in the last quarter.
Get CureVac alerts:CureVac Price Performance
CureVac stock opened at $9.70 on Monday. CureVac has a 12-month low of $9.35 and a 12-month high of $71.63. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06. The firm has a 50 day simple moving average of $13.14 and a 200-day simple moving average of $15.71.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reissued a "buy" rating and set a $37.00 price target on shares of CureVac in a report on Thursday, June 9th.About CureVac
(Get Rating)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
Read More
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC – Get Rating).
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
Martingale Asset Management L P acquired a new position in CureVac (NASDAQ:CVAC – Get Rating) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 41,042 shares of the company's stock, valued at approximately $805,000.
根据美国证券交易委员会的最新披露,该公司在第一季度收购了CureVac(纳斯达克:CVAC-GET评级)的一个新头寸。该公司收购了41,042股该公司股票,价值约805,000美元。
Other hedge funds have also recently bought and sold shares of the company. Capital Fund Management S.A. grew its position in CureVac by 131.9% in the 1st quarter. Capital Fund Management S.A. now owns 233,371 shares of the company's stock worth $4,576,000 after purchasing an additional 132,757 shares during the last quarter. California Public Employees Retirement System grew its holdings in CureVac by 0.6% in the 4th quarter. California Public Employees Retirement System now owns 120,622 shares of the company's stock worth $4,139,000 after buying an additional 735 shares in the last quarter. Bank of New York Mellon Corp increased its position in CureVac by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 103,549 shares of the company's stock valued at $2,030,000 after acquiring an additional 2,286 shares during the period. Eversept Partners LP acquired a new stake in CureVac in the 4th quarter valued at approximately $2,917,000. Finally, Bank of America Corp DE raised its stake in CureVac by 246.6% during the 4th quarter. Bank of America Corp DE now owns 72,885 shares of the company's stock valued at $2,501,000 after acquiring an additional 51,856 shares in the last quarter.
其他对冲基金最近也买卖了该公司的股票。资本基金管理公司第一季度在CureVac的持仓增加了131.9%。Capital Fund Management S.A.现在持有233,371股该公司股票,价值4,576,000美元,在上个季度又购买了132,757股。加州公共雇员退休系统第四季度在CureVac的持有量增加了0.6%。加州公共雇员退休系统现在拥有120,622股该公司股票,价值4,139,000美元,上个季度又购买了735股。纽约梅隆银行(Bank Of New York Mellon Corp)第一季度将CureVac的头寸增加了2.3%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有103,549股该公司股票,价值2,030,000美元,在此期间又购买了2,286股。Eversept Partners LP在第四季度收购了CureVac的新股份,价值约291.7万美元。最后,美国银行在第四季度将其在CureVac的持股比例提高了246.6%。美国银行DE目前持有72,885股该公司股票,价值2,501,000美元,此前该公司在上一季度增持了51,856股。
CureVac Price Performance
CureVac性价比
CureVac stock opened at $9.70 on Monday. CureVac has a 12-month low of $9.35 and a 12-month high of $71.63. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06. The firm has a 50 day simple moving average of $13.14 and a 200-day simple moving average of $15.71.
CureVac股票周一开盘报9.70美元。CureVac的12个月低点为9.35美元,12个月高位为71.63美元。该公司的流动比率为3.45,速动比率为3.39,债务权益比率为0.06。该公司的50日简单移动均线切入位在13.14美元,200日简单移动均线切入位在15.71美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
About CureVac
关于CureVac
(Get Rating)
(获取评级)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
CureVac N.V.是一家临床阶段的生物制药公司,专注于开发基于信使核糖核酸(MRNA)的各种变革性药物。它正在开发预防疫苗,如处于SARS-CoV-2第一阶段临床试验的mRNA候选疫苗CV2CoV;已完成狂犬病病毒糖蛋白第一阶段临床试验的基于mRNA的预防性疫苗CV7202;处于流感第一阶段临床试验的CVSQIV,以及拉沙热、黄热病、呼吸道合胞病毒、轮状病毒、疟疾和通用流感疫苗。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免费获取StockNews.com关于CureVac(CVAC)的研究报告
- 随着管理层重组,股市能否迅速反弹?
- MarketBeat:回顾中的一周8/29-9/2
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖,但仍被高估吗?
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC – Get Rating).
想看看还有哪些对冲基金持有CVAC吗?访问HoldingsChannel.com获取CureVac(纳斯达克代码:CVAC-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
接受CureVac Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对CureVac和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧